These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18514657)

  • 1. The art of choosing sound study endpoints.
    Hanson B
    Injury; 2008 Jun; 39(6):656-8. PubMed ID: 18514657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Health related quality of life and endpoints in oncology].
    Bonnetain F
    Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dependence, hyper-dependence and hypothesis testing in clinical trials.
    Moyé LA; Baraniuk S
    Contemp Clin Trials; 2007 Jan; 28(1):68-78. PubMed ID: 16857430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An efficient method for accommodating potentially underpowered primary endpoints.
    Li J; Mehrotra DV
    Stat Med; 2008 Nov; 27(26):5377-91. PubMed ID: 18759248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inclusion of health-related quality of life studies alongside clinical trials: basis and practical recommendations. Utilization of a check-list for their correct desing and evaluation].
    Soto Alvarez J
    An Med Interna; 2003 Dec; 20(12):633-44. PubMed ID: 14697086
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulmonary rehabilitation and clinical trial design in patients with severe COPD.
    Springmeyer SC; Casaburi R; Make B; Jones P; Wise R
    COPD; 2008 Oct; 5(5):305-9. PubMed ID: 18972279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing the best endpoint.
    Christensen E
    J Hepatol; 2008 Oct; 49(4):672-3. PubMed ID: 18718690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consultants' forum: should post hoc sample size calculations be done?
    Walters SJ
    Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size in clinical trials with dichotomous endpoints: use of covariables.
    Choi SC
    J Biopharm Stat; 1998 Jul; 8(3):367-75. PubMed ID: 9741853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect measure for quantitative endpoints: statistical versus clinical significance, or "how large the scale is?".
    Baicus C; Caraiola S
    Eur J Intern Med; 2009 Sep; 20(5):e124-5. PubMed ID: 19712834
    [No Abstract]   [Full Text] [Related]  

  • 15. Surrogate endpoints: do they really contribute in therapeutic decision making?
    Ray K; Sarkar PK
    J Assoc Physicians India; 1999 Sep; 47(9):894-6. PubMed ID: 10778660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of endpoint shopping on power in confirmatory clinical trials.
    Wiens BL
    J Biopharm Stat; 2003 May; 13(2):229-40. PubMed ID: 12729391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 18. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
    D'Souza M; Kappos L; Czaplinski A
    J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choices.
    Savitz SI; Benatar M; Saver JL; Fisher M
    Cerebrovasc Dis; 2008; 26(2):156-62. PubMed ID: 18560219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The profile of the one-time 1572 investigator.
    Glass HE
    Contemp Clin Trials; 2009 Jan; 30(1):34-9. PubMed ID: 18835461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.